Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-881 in Primary Immunodeficiency Diseases (PIDD)
NCT05755035Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2023
- Primary completion
- Jan 2026
- Modality
- SC (Subcutaneous administration)
- Countries
- 8
01
Overview
A Phase 3 trial of TAK-881 in primary immunodeficiency disease (PID), sponsored by Takeda. Started Oct 2023; status: completed.
02
Drugs
TAK-881
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT05755035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755035.